BOSTON (TheStreet) -- A calendar of important, potentially stock-moving biotech events for February:

Feb. 2
Ironwood Pharmaceuticals ( IRWD) initial public offering.

Feb 8 - 9
BIO CEO Conference, New York.

Feb. 9
FDA approval decision date for GlaxoSmithKline ( GSK - Get Report) and Xenoport's ( XNPT) Solzira for restless leg syndrome.

Feb. 10
FDA Oncologic Drug Advisory Committee meeting to discuss Cell Therapeutics' ( CTIC - Get Report) lymphoma drug pixantrone. FDA's briefing documents for this meeting likely available Feb. 8 - 9.

Micromet ( MITI) investor/analyst day.

Feb. 11
FDA approval decision date for Labopharm's ( DDSS) trazadone contramid for major depressive disorder.

Feb. 12
FDA approval decision date for Cadence Pharmaceuticals' ( CADX) Acetevance (intravenous acetaminophan) for hospital use.

Feb. 13
FDA approval decision date for Gilead Sciences' ( GILD - Get Report) Cayston antibiotic for cystic fibrosis.

Feb. 16-19
Conference on Retroviruses and Opportunistic Infections (CROI), San Francisco
Gilead will be presenting phase II data on its "Quad pill" for HIV.

Feb. 23
FDA advisory panel to review Salix Pharmaceuticals' ( SLXP) Xifaxan in hepatic encephalopathy.

Feb 25
ImmunoGen ( IMGN - Get Report) investor/analyst meeting.

Feb. 28
FDA approval decision date for Shire's ( SHPGY) velaglucerase in Gaucher's disease.

Ongoing FDA reviews with no firm decision date:

Auxillium Pharmaceuticals ( AUXL) and Pfizer's ( PFE - Get Report) Xiaflex for Dupuytren's Contracture.

Mannkind's ( MNKD) Afresa (inhaled insulin) for diabetes.

-- Reported by Adam Feuerstein in Boston.

Follow Adam Feuerstein on Twitter.

Adam Feuerstein writes regularly for TheStreet.com. In keeping with TSC's editorial policy, he doesn't own or short individual stocks, although he owns stock in TheStreet.com. He also doesn't invest in hedge funds or other private investment partnerships. Feuerstein appreciates your feedback; click here to send him an email.